ANDRE NEDER RAMIRES ABDO
Índice h a partir de 2011
8
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
conferenceObject 96-Week Update from the Phase 3 ASCEMBL Study for Evaluating the Safety and Efficacy of Asciminib versus Bosutinib in Patients with chronic phase chronic myeloid Leukemia after Pretreatment with 2 TKIs(2022) HOCHHAUS, A.; REA, D.; SAUSSELE, S.; BUSKE, S.; BALABANOV, S.; LANG, F.; SAUER, T.; GATTERMANN, N.; MAURO, M.; MINAMI, Y.; LOMAIA, E.; VOLOSHIN, S.; TURKINA, A.; KIM, D. -W; APPERLEY, J.; CORTES, J.; ABDO, A.; FOGLIATTO, L. M.; KIM, D.; ANNUNZIATA, M.; HUGHES, T.; CHAUDHRI, N.; CHEE, L.; GARCIA-GUTIERREZ, V; SASAKI, K.; KAPOOR, S.; ALLEPUZ, A.; QUENET, S.; BEDOUCHA, V; BOQUIMPANI, C.; COUTRE, P. le- Clinical, laboratory and genetic features of Erdheim-Chester disease patients: analysis of a retrospective cohort of two reference centers in Latin America(2022) BRANDAO, Antonio Adolfo Guerra Soares; ABDO, Andre Ramires Neder; LAGE, Luis Alberto de Padua Covas; FATOBENE, Giancarlo; PEREIRA, Juliana; ROCHA, VandersonObjectives and Methods: Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm with a heterogeneous clinical course, ranging from localized and asymptomatic bone lesions to a multisystem disease, causing significant morbidity and mortality. There are few cohorts published, mainly from North America and Europe. We retrospectively collected clinical data on sixteen biopsy-proven ECD patients diagnosed and treated at two Brazilian reference centres for histiocytic disorders from January 2006 to February 2020. Results: Median time from onset of symptoms to diagnosis was 13 months (0.1-142). The main organ involved in ECD was bone (75%) and also 75% of the patients presented involvement of more than one organ, characterizing a multi-organic form. BRAF status was available in 81.2% of patients and BRAF V600E mutation was detected by Sanger sequencing in only 18.8%, which can be explained by the low sensitivity of this technique. All patients were treated due to symptomatic disease and a median of two lines (range: 1-7) of therapy were needed. The most common first-line therapy used was alpha-interferon (75%). The median progression-free survival was 7.5 months, and the median OS was not reached. Discussion and Conclusion: In the largest Latin American cohort of patients with ECD reported to date, we observed findings which resemble demographic characteristics, sites of involvement and treatment choices reported by other groups. The outcomes may be better with target therapies such as BRAF and MEK inhibitors in patients with mutation and with the adoption of recently published consensus recommendations for the management of ECD patients.
- Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia(2022) SANTOS, Fernanda Maria; GHELFOND, Giovanna; SEGURO, Fernanda Salles; ABDO, Andre Neder R.; DALESSANDRO, Thales; MACIEL, Felipe Vieira R.; BASSOLLI, Lucas; ROCHA, Vanderson; BENDIT, Israel
- Oncohematology(2022) SAPELLI, J.; FILHO, J. S.; BAIOCCHI, O. C. C. G.; BACHOUR, P.; ABDO, A. N. R.; BOMBONATTI, J. F.; LóSS, S. R.; LANGHI, M. M.Hematological neoplasms (HN) are a category of cancers that originate from hematopoietic cells. They are mainly classified as leukemias, lymphomas, and multiple myeloma and myelodysplastic syndromes. Due to the evolution of therapy, currently there has been a reduction in mortality rates, turning these neoplasms into chronic diseases. Therefore, more elderly people with multiple comorbidities have been submitted to therapy leading to previously unknown adverse events. Vascular complications of chemotherapy are common examples and may occur as a result of “off-target” drug effects or, importantly, as a result of the significant overlap between signaling pathways required for normal vascular function and those required for tumor growth. Direct tumor effects can also lead to vascular complications such as vascular obstruction and thrombosis. The objective of this chapter is to discuss the most common mechanisms of vascular complications and its therapeutic approaches. © Springer Nature Switzerland AG 2022.